Safety & Efficacy Study of LX103 Treatment of X-Linked Retinoschisis

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06066008` - Safety and Efficacy Study of Novel Gene Therapy ZM-01 for X-linked Retinoschisis Patients	Early Phase 1
Completed	`NCT02331173` - Clinical Evaluation of Patients With X-linked Retinoschisis	N/A
Completed	`NCT02416622` - Safety and Efficacy of rAAV-hRS1 in Patients With X-linked Retinoschisis (XLRS)	Phase 1/Phase 2
Recruiting	`NCT05878860` - ATSN-201 Gene Therapy in RS1-Associated X-linked Retinoschisis	Phase 1/Phase 2

See also

Status

Clinical Trial

Phase

Recruiting

NCT06066008 - Safety and Efficacy Study of Novel Gene Therapy ZM-01 for X-linked Retinoschisis Patients

Early Phase 1

Completed

NCT02331173 - Clinical Evaluation of Patients With X-linked Retinoschisis

N/A

Completed

NCT02416622 - Safety and Efficacy of rAAV-hRS1 in Patients With X-linked Retinoschisis (XLRS)

Phase 1/Phase 2

Recruiting

NCT05878860 - ATSN-201 Gene Therapy in RS1-Associated X-linked Retinoschisis

Phase 1/Phase 2

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NCT number	NCT05814952
Study type	Interventional
Source	Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Contact
Status	Recruiting
Phase	N/A
Start date	December 13, 2022
Completion date	August 2028

Safety and Efficacy Study of LX103 Treatment of X-Linked Retinoschisis (XLRS)

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms